Delivery Order SPE2DB24D9803-SPE2DB26FJRWS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,523.54 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Telmisartan 20 mg tablets (30-count units). The award, issued on October 21, 2025, with an ultimate completion date of October 22, 2025, utilizes a firm fixed-price contract structure with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,678.00 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Telmisartan 40 mg tablets (30-count units). This firm fixed-price delivery order, which must be completed by September 18, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location. The...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,135.44 firm fixed-price delivery order is for the supply of Telmisartan 20 mg tablets and does not have a set-aside designation. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,367.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30-count). The award was issued on August 12, 2025, with an ultimate completion date of August 13, 2025, and does not utilize a set-aside designation. Performance will take place in Conshohocken, Pennsylvania. This delivery order is issued...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a firm fixed-price delivery order ceiling value of $4,541.76 and covers the supply of Telmisartan 20 mg tablets to fulfill the recurring pharmaceutical needs of military health facilities. DMS Pharmaceutical Group holds a larger indefinite-delivery contract (IDC) with the DLA under the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,950.22 by the Defense Logistics Agency (DLA) on August 22, 2025. The delivery order, issued under DLA's larger Indefinite Delivery Contract (SPE2DB program) valued at $499.999 billion and valid through November 2026, calls for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count)....
- This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,671.69 firm fixed-price delivery order is for the provision of Telmisartan 40 mg tablets to support the recurring pharmaceutical supply needs of U.S. military healthcare facilities. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) under its SPE2DB program. The award has a ceiling value of $9,210.24 and covers the delivery of 4554944974 - Telmisartan 40 mg Tablets 30s to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $30,173.10 by the Defense Logistics Agency's Medical Supply Chain division on October 20, 2025. This firm fixed-price delivery order represents one of numerous awards issued to DMS Pharmaceutical Group under its broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract, which carries a $500...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,844.15 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on October 24, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V program is a $30.3...
- SPE2DB24D9803Indefinite Delivery Contract
- SPE2DB24D9803-SPE2DB26FJRWSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,120.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Telmisartan 40 mg tablets (30-count units). The award was issued on October 27, 2025, with an ultimate completion date of October 28, 2025, under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued pursuant to DMS Pharmaceutical Group's single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that authorizes DLA to procure a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical pharmaceutical supplier within the DoD medical supply chain, with recent delivery orders spanning oncology treatments, biologics, vaccines, emergency medications, and routine pharmaceuticals. The vendor's established performance across multiple product categories and pricing ranges, combined with its small business status, positions it competitively within the broader $30.3 billion PPV-G GEN V acquisition strategy. The company maintains no identified subcontractor relationships and operates as a direct supplier to federal agencies, leveraging its comprehensive pharmaceutical distribution capabilities to fulfill specialized medical supply requirements for military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/27/25 |